AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05719857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic vein pressure gradient measurement
Description: HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
Study NCT05719857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous liver biopsy
Description: Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
Study NCT05719857 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric Abdominal Magnetic Resonance with Elastography
Description: The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
Study NCT06369597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: Local laparoscopic surgery
Study NCT06507319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct bone anchored pull distal slider
Description: distalization from the palatal side only.
Study NCT06507319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect bone anchored dual force distalizer.
Description: distalization from the palatal and buccal sides.
Study NCT04993092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle energy technique
Description: Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
Study NCT04993092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan mobilization technique
Description: Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
Study NCT05481944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI in patients
Description: Injected MRI
Study NCT05481944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: MRI in healthy volunteers
Description: non injected MRI
Study NCT04905836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
Study NCT04905836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient solution
Study NCT05322083 — intervention group
Intervention type: DRUG
Intervention: Doravirine
Description: Doravirine will be given to patients after failure on the first NNRTI regimen.
Study NCT06244407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets
Description: Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
Study NCT06244407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets
Description: Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
Study NCT06499415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU-Calcipotriol
Description: topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
Study NCT06499415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU 50 MG/ML Topical Cream
Description: topical 5FU, twice daily, 7 days a week, during 4 weeks
Study NCT06661135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLPD total laparoscopic pancreaticoduodenectomy
Description: It includes removal of the pancreatic or duodenal tumors using the laparoscopy
Study NCT06661135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OPD open pancreaticoduodenectomy
Description: It includes removal of the pancreatic or duodenal tumors using the open technique
Study NCT06661811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T cells
Study NCT06661200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMC signal recording
Description: SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
Study NCT06662110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PSRscore
Description: PSRscore calculated based on baseline serum immune proteomics
Study NCT06658327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Description: Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
Study NCT06658327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
Study NCT06660680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Received MBI treatment to their surgical incisions upon completion of surgery
Study NCT06659133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play
Study NCT06659653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRG2302
Description: Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
Study NCT06661512 — intervention group
Intervention type: OTHER
Intervention: Neurorehabilitation program
Description: Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral).
Study NCT06660511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin in Combination With Anlotinib Hydrochloride
Description: The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)
Study NCT06614101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exhaled air analysis
Description: The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
Study NCT04926636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and Wellness Coaching
Description: An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
Study NCT05273255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Single-dose of fecal microbiota from FMT-Donor transplanted endoscopically to FMT-Recipient in between two cycles of CI.
Study NCT05820139 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Group
Description: Patients will be randomized to a 200mL (control group)
Study NCT05820139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Test Group
Description: Patients will be randomized to a cut-off of 150mL (test group)
Study NCT06440954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal pemetrexed
Description: Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
Study NCT04837118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive handouts containing dietary recommendations
Study NCT04837118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04837118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04837118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participate in a resistance training program
Study NCT05223959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted Psychoeducation
Description: This is a culturally adapted psychoeducation program consisting of 12 sessions. Each CaPE session lasts for approximately 60 minutes, beginning with a 20-30-minute presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for recurrence).
Study NCT05045482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 1 mg
Description: Group-8: Total of 12 subjects will be enrolled in the Group-8. Group 8A (n=3, consist of mild hepatic impairment subjects); Group 8B (n=3, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
Study NCT05045482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
Study NCT05730556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerivio ®
Description: Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
Study NCT05730556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Electrical stimulation to mimic study treatment intervention
Study NCT06129474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor deprescribing tool
Description: The intervention is targeted to the Swiss Primary care practice. It involves educational material and resources to guide the safe deprescribing of inappropriate PPIs, for both general practitioners and patients.
Study NCT06130254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO BID
Study NCT06130254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given by PO BID
Study NCT05132400 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological-informed Physical Therapy (PiPT) Training
Description: An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
Study NCT05915195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural and Kinesthetic Awarness
Description: Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
Study NCT05915195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
Study NCT06463431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: We propose a conceptual model for the relationship between PTSD, substance use, \& sexual risk behaviour wherein using substances to avoid posttraumatic cognitions \& affect leads to risky sexual behaviour through impaired safer sex negotiation. These mechanisms are consistent with the theory underlying CPT. Behaviourally, substance use (and potentially risky sexual behaviour) is negatively reinforced through avoiding unwanted negative affect. Cognitively, PTSD-based predictions may generate unrealistic risk appraisals that contribute to sexual risk. CPT addresses these specified pathways by a) identifying how trauma leads to maladaptive beliefs about the self, others, \& the future, b) cognitive interventions to address these beliefs, \& c) an overall trauma-focused orientation that addresses cognitive, affective \& behavioural avoidance, using cognitive restructuring to lead to more realistic/adaptive beliefs, less cognitive/affective avoidance, \& more goal-directed approach behaviours.
Study NCT06091943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab IV
Description: Planned doses will be administered intravenously.
Study NCT06091943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab SC
Description: Planned doses will be administered via subcutaneous injection.
Study NCT06091943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histology-Based Chemotherapy Doublet
Description: Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Study NCT05532722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: Given subcutaneous injection
Study NCT05767398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered as a tablet or capsule
Study NCT06416150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 SOC
Description: Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
Study NCT06416150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 HERS
Description: Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
Study NCT05018143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS
Description: This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.
Study NCT05018143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: In this intervention, participants will receive the safety planning intervention.
Study NCT05087563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolens spectacle lens
Description: spectacle lens
Study NCT05087563 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spectacle lens
Description: spectacle lens for refractive correction
Study NCT05601765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard communication pathways after discharge
Description: Standard communication pathways after discharge
Study NCT05601765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital team-based communication after discharge
Description: Standard communication pathways plus digital team-based communication after discharge
Study NCT05091073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
Study NCT05091073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0385-0434
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
Study NCT04893395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Screening
Description: First telehealth appointment:~1. Pharmacogenomics education and informed consent~2. Medical history~3. Sample collection~Second telehealth appointment:~1. Results of pharmacogenomic testing~2. Utility and limitations of pharmacogenomic testing~3. Patient-specific potential impacts on current or future medication therapies~4. Answering of patient questions~5. Referral to mental health provider(s) for treatment-specific recommendations
Study NCT05614700 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: High Dose-Rate Brachytherapy
Study NCT05614700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic Body Radiotherapy
Description: Hypofractionated External Beam Radiotherapy
Study NCT04839809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Oral